We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

277 hedge funds and large institutions have $7.86B invested in Alnylam Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 111 increasing their positions, 79 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 24

59% more call options, than puts

Call options by funds: $95.3M | Put options by funds: $59.8M

41% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 79

17% more funds holding

Funds holding: 237 → 277 (+40)

17% more capital invested

Capital invested by funds: $6.73B → $7.86B (+$1.13B)

8% less funds holding in top 10

Funds holding in top 10: 12 → 11 (-1)

Holders
277
Holders Change
+40
Holders Change %
+16.88%
% of All Funds
7.46%
Holding in Top 10
11
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-8.33%
% of All Funds
0.3%
New
65
Increased
111
Reduced
79
Closed
24
Calls
$95.3M
Puts
$59.8M
Net Calls
+$35.5M
Net Calls Change
+$14.3M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$53.7M
2
State Street
State Street
Massachusetts
+$36.5M
3
First Trust Advisors
First Trust Advisors
Illinois
+$36M
4
TCIM
TIAA CREF Investment Management
New York
+$32.7M
5
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
+$27.2M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$98.8M
2
CWAM
Columbia Wanger Asset Management
Illinois
-$42M
3
AWG
Alpha Wave Global
New York
-$39.9M
4
GGHC
Gilder Gagnon Howe & Co
New York
-$28.9M
5
JP Morgan Chase
JP Morgan Chase
New York
-$27.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Legal & General Group
126
Legal & General Group
United Kingdom
$3.08M +$2.8M +23,389 +1,009%
ACM
127
Atika Capital Management
New York
$2.88M +$2.21M +18,500 +336%
HSBC Holdings
128
HSBC Holdings
United Kingdom
$2.8M +$2.21M +18,473 +376%
GIBU
129
Gulf International Bank (UK)
United Kingdom
$2.74M +$2.73M +22,880 New
NIP
130
Nicholas Investment Partners
California
$2.58M -$3.21M -26,821 -55%
MOACM
131
Mutual of America Capital Management
New York
$2.58M -$206K -1,725 -7%
Los Angeles Capital Management
132
Los Angeles Capital Management
California
$2.54M -$16.9M -141,825 -87%
FAF
133
Fjarde Ap-fonden
Sweden
$2.52M +$2.51M +21,037 New
ARTA
134
A.R.T. Advisors
New York
$2.52M -$1.35M -11,294 -35%
PP
135
Paloma Partners
Connecticut
$2.5M +$658K +5,502 +36%
HI
136
HBK Investments
Texas
$2.25M -$4.12M -34,503 -65%
Two Sigma Investments
137
Two Sigma Investments
New York
$2.23M +$2.23M +18,630 New
CAM
138
Chesapeake Asset Management
New York
$2.21M – – –
ACI
139
AMP Capital Investors
Australia
$2.18M +$2.28M +19,059 New
IRF
140
IBM Retirement Fund
New York
$2.17M +$289K +2,422 +15%
TD Asset Management
141
TD Asset Management
Ontario, Canada
$2.17M +$370K +3,100 +21%
Public Employees Retirement Association of Colorado
142
Public Employees Retirement Association of Colorado
Colorado
$2.14M +$3.35K +28 +0.2%
QI
143
QS Investors
New York
$2.05M +$2.04M +17,100 New
BCIM
144
British Columbia Investment Management
British Columbia, Canada
$1.94M +$1.93M +16,154 New
Macquarie Group
145
Macquarie Group
Australia
$1.83M -$548K -4,587 -23%
SG Americas Securities
146
SG Americas Securities
New York
$1.74M +$1.21M +10,165 +234%
CSS
147
Cubist Systematic Strategies
Connecticut
$1.73M +$1.65M +13,840 +2,346%
FAM
148
Fortaleza Asset Management
Illinois
$1.6M -$810K -6,780 -34%
Arrowstreet Capital
149
Arrowstreet Capital
Massachusetts
$1.59M +$1.59M +13,274 New
KFS
150
Kurt F. Somerville
$1.58M -$19.1K -160 -1%
4 5
6
7 8

ALNY Hedge Fund Activity: Q2 2015 in Review

277 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2015, worth a combined $7.86B — up 17% from $6.73B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new ALNY positions and 24 closed out — a net gain of 41 holders — while 111 added to existing stakes and 79 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $53.7M. The largest seller was Wellington Management Group, cutting an estimated $98.8M.

  • 277 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2015, up from 237 in Q1 2015.
  • Funds reported $7.86B of Alnylam Pharmaceuticals stock for Q2 2015, up 17% quarter-over-quarter.
  • 65 funds opened new Alnylam Pharmaceuticals positions in Q2 2015 and 24 closed out, a net change of +41 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q2 2015 was T. Rowe Price Associates, an estimated $53.7M added.
  • The largest Alnylam Pharmaceuticals seller in Q2 2015 was Wellington Management Group, an estimated $98.8M sold.

Based on aggregated 13F filings for Q2 2015.